Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Impact Therapeutics (英派药业) IPO Trading

Impact Therapeutics (英派药业) Pre-IPO: Thoughts on Valuation

Impact Therapeutics (英派药业) Pre-IPO: Post Senaparib Commercialization, What's Next?

Impact Therapeutics (英派药业) Pre-IPO: Credible R&D in PARP

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

IMPACT Therapeutics / Equity Capital Markets

<ul>
<li>Impact Therapeutics, a China-based biotech, launched its IPO to raise at least USD 116 million via a Hong Kong listing.</li>
<li>In this note, we look at the deal terms and recap our valuation thoughts for the company.</li>
<li>We also look at the main reason that caps the return of the deal.</li>
</ul>


Impact Therapeutics, a China-based biotech, launched its IPO to raise at least USD 116 million via a Hong Kong listing.
In this note, we look at the deal terms and recap our valuation thoughts for the company.
We also look at the main reason that caps the return of the deal.


Impact Therapeutics (英派药业) IPO: Mind the Catalysts in 2H2026